Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably. We used gene expression profiling to develop a more precise molecular diagnosis of PMBL. PMBL patients were considerably younger than other DLBCL patients, and their lymphomas frequently involved other thoracic structures but not extrathoracic sites typical of other DLBCLs. PMBL patients had a relatively favorable clinical outcome, with a 5-yr survival rate of 64% compared with 46% for other DLBCL patients. Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkin lymphoma cells. PDL2, which encodes a regulator of T cell activation, was the gene that best discriminated PMBL from other DLBCLs and was also highly expressed in Hodgkin lymphoma cells. The genomic loci for PDL2 and several neighboring genes were amplified in over half of the PMBLs and in Hodgkin lymphoma cell lines. The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL.

[1]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  yang-xin fu,et al.  B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism , 2003, The Journal of experimental medicine.

[3]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[4]  Lieping Chen,et al.  B7-H1 pathway and its role in the evasion of tumor immunity , 2003, Journal of Molecular Medicine.

[5]  C. Copie-Bergman,et al.  Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. , 2003, Blood.

[6]  Andrea Califano,et al.  Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. , 2003, The Journal of clinical investigation.

[7]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[8]  C. Copie-Bergman,et al.  MAL Expression in Lymphoid Cells: Further Evidence for MAL as a Distinct Molecular Marker of Primary Mediastinal Large B-Cell Lymphomas , 2002, Modern Pathology.

[9]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[10]  T. Barth,et al.  Mediastinal (thymic) large B-cell lymphoma: where do we stand? , 2002, The Lancet. Oncology.

[11]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[12]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[13]  B. Coiffier,et al.  Diffuse large cell lymphoma. , 2001, Current opinion in oncology.

[14]  S. Poppema,et al.  TARC, a CC Chemokine, Is Frequently Expressed in Classic Hodgkin's Lymphoma But Not in NLP Hodgkin's Lymphoma, T-Cell-Rich B-Cell Lymphoma, and Most Cases of Anaplastic Large Cell Lymphoma , 2001, The American journal of surgical pathology.

[15]  H. Döhner,et al.  Gain of chromosome arm 9p is characteristic of primary mediastinal b‐cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line , 2001, Genes, chromosomes & cancer.

[16]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[17]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[18]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[19]  P. Marynen,et al.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. , 2000, Cancer research.

[20]  Giffen Jw.  Hodgkin's disease , 1980, Bone Marrow Transplantation.

[21]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[22]  S. Pileri,et al.  Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. , 1999, Blood.

[23]  W. Wilson,et al.  CNS involvement in primary mediastinal large B-cell lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Chan,et al.  Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Lichter,et al.  Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. , 1996, Blood.

[27]  M. Dyer,et al.  B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. , 1994, Blood.

[28]  E. Jaffe,et al.  The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Konrad Donhuijsen.  Patterns of presentation of Hodgkin disease , 1993, Cancer.

[30]  L. Kalish,et al.  Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis , 1993, Cancer.

[31]  N. Harris,et al.  The relationship between Hodgkin's disease and non-Hodgkin's lymphoma. , 1992, Seminars in diagnostic pathology.

[32]  E. Jaffe,et al.  Non-Hodgkin's Lymphomas Arising in Patients Successfully Treated for Hodgkin's Disease: A Clinical, Histologic, and Immunophenotypic Study of 14 Cases , 1992, The American journal of surgical pathology.

[33]  D. Charlier,et al.  A study of 15 cases of primary mediastinal lymphoma of B‐cell type , 1992, Cancer.

[34]  E. Jaffe,et al.  Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. , 1991, American journal of clinical pathology.

[35]  P. Gaulard,et al.  Mediastinal Diffuse Large‐Cell Lymphoma with Sclerosis: A Condition with a Poor Prognosis , 1989, American journal of clinical oncology.

[36]  A. Norton,et al.  THE HUMAN THYMUS CONTAINS A NOVEL POPULATION OF B LYMPHOCYTES , 1987, The Lancet.

[37]  P. Isaacson,et al.  Large cell lymphoma of the mediastinum: a B‐cell tumour of probable thymic origin , 1986, Histopathology.

[38]  V. Diehl,et al.  Evidence for the detection of the normal counterpart of hodgkin and sternberg‐reed cells , 2007, Hematological oncology.